TOP > 外国特許検索 > THERAPEUTIC AGENT FOR CHRONIC MYELOID LEUKEMIA

THERAPEUTIC AGENT FOR CHRONIC MYELOID LEUKEMIA

外国特許コード F170008948
整理番号 14084
掲載日 2017年2月16日
出願国 世界知的所有権機関(WIPO)
国際出願番号 2016JP060803
国際公開番号 WO 2016159301
国際出願日 平成28年3月31日(2016.3.31)
国際公開日 平成28年10月6日(2016.10.6)
優先権データ
  • 特願2015-075195 (2015.4.1) JP
発明の名称 (英語) THERAPEUTIC AGENT FOR CHRONIC MYELOID LEUKEMIA
発明の概要(英語) A safe and effective CML stem cell remover, a TKI-resistant suppressant, and a multi-kinase inhibitor-resistant suppressant are provided as a result of revealing this novel signal transduction pathway involved in maintaining chronic myeloid leukemia stem cells and selectively inhibiting the signal. With this, a therapeutic drug for relapse of CML and Ph+ALL and a preventative drug for relapse of CML and Ph+ALL are provided. The therapeutic agent for chronic myeloid leukemia contains a selective inhibitor of the p38 MAPK signal. The therapeutic agent is combined with a tyrosine kinase inhibitor or a multi kinase inhibitor.
特許請求の範囲(英語) [claim1]
1. Containing the selective obstruction medicine of the P38 MAPK signal, it becomes, the chronic marrow characteristic leukemia remedy medicine.
[claim2]
2. It is something where the obstruction medicine obstructs p38.alpha. and p38.beta., the medicine of claim 1 statement.
[claim3]
3. The obstruction medicine LY2228820, VX-702 and BIRB is selected from the group which consists of 796 and those salts, claim the medicine of 1 or 2 statements.
[claim4]
4. The obstruction medicine LY2228820 or is that salt, the medicine of claim 3 statement.
[claim5]
5. It is the removal medicine of the chronic marrow characteristic leukemia trunk cell, either of the claim 1-4 in 1 sections the medicine of statement.
[claim6]
6. It is the inhibiter of the resistant chronic marrow characteristic leukemia trunk cell vis-a-vis the thyrosin kinase obstruction medicine, either of the claim 1-4 in 1 sections the medicine of statement.
[claim7]
7. It becomes combining with the thyrosin kinase obstruction medicine or the multiple kinase obstruction medicine, either of the claim 1-6 in 1 sections the medicine of statement.
[claim8]
8. The thyrosin kinase obstruction medicine is [imachinibu], [dasachinibu], [bosuchinibu], [radochinibu] or [nirochinibu], the multiple kinase obstruction medicine is KW2449 or [ponachinibu], the medicine of claim 7 statement.
  • 出願人(英語)
  • ※2012年7月以前掲載分については米国以外のすべての指定国
  • HIROSHIMA UNIVERSITY
  • 発明者(英語)
  • NAKA KAZUHITO
国際特許分類(IPC)
指定国 (WO2016159301)
National States: AE AG AL AM AO AT AU AZ BA BB BG BH BN BR BW BY BZ CA CH CL CN CO CR CU CZ DE DK DM DO DZ EC EE EG ES FI GB GD GE GH GM GT HN HR HU ID IL IN IR IS KE KG KN KP KR KZ LA LC LK LR LS LU LY MA MD ME MG MK MN MW MX MY MZ NA NG NI NO NZ OM PA PE PG PH PL PT QA RO RS RU RW SA SC SD SE SG SK SL SM ST SV SY TH TJ TM TN TR TT TZ UA UG US UZ VC VN ZA ZM ZW
ARIPO: BW GH GM KE LR LS MW MZ NA RW SD SL SZ TZ UG ZM ZW
EAPO: AM AZ BY KG KZ RU TJ TM
EPO: AL AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HR HU IE IS IT LT LU LV MC MK MT NL NO PL PT RO RS SE SI SK SM TR
OAPI: BF BJ CF CG CI CM GA GN GQ GW KM ML MR NE SN ST TD TG

PAGE TOP

close
close
close
close
close
close